Skip to main content

Osteomalacia News

Perfluorooctanesulfonic Acid Exposure Linked to Lower Bone Density

WEDNESDAY, Dec. 13, 2023 – In a cohort of Hispanic adolescents and young adults, plasma perfluorooctanesulfonic acid (PFOS) exposure is associated with lower bone mineral density (BMD), according to...

Ultragenyx and Kyowa Kirin Announce U.S. FDA Approval of Crysvita (burosumab) for the Treatment of Tumor-Induced Osteomalacia (TIO)

NOVATO, Calif. and TOKYO, June 18, 2020 (GLOBE NEWSWIRE) – Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Osteoporosis

Related drug support groups

Vitamin D